Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)

10. juni 2015 opdateret af: AbbVie (prior sponsor, Abbott)

Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice

The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

This was a postmarketing observational study (PMOS) for participants with insufficiently controlled, moderate to severe, active AS who were eligible for adalimumab therapy. Participants started treatment with adalimumab under normal clinical settings in Germany. Enrolled participants were followed during adalimumab therapy . Participants were assessed during regular clinic visits for up to 24 months and 359 clinicians (rheumatologists/orthopedists/general practitioners/internist) participated in the study. Since this was an observational trial, not all doctors followed the stated age limitations and some participants under the age of 18 were enrolled.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

4681

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants with AS in routine clinical practice.

Beskrivelse

Inclusion Criteria:

  1. Participants with active, AS for at least 4 weeks (BASDAI greater than or equal to 4).
  2. Participants who failed treatment with two non-steroidal anti-inflammatory drugs (NSAIDs).
  3. No contraindications for anti-tumor necrosis factors (TNF) therapy.

Exclusion Criteria:

1. Participants who do not meet the above listed inclusion criteria.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: Kun etui
  • Tidsperspektiver: Fremadrettet

Kohorter og interventioner

Gruppe / kohorte
Ankylosing spondylitis
Participants with ankylosing spondylitis

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The BASDAI was a six question, participant-reported measure of overall disease activity that probed the level of fatigue, neck/back/hip pain, peripheral joint swelling and pain, localized tenderness, as well as morning stiffness severity and duration. It was scored on a numerical rating scale that ranged from 0 (no symptoms) to 10 (severe symptoms), and the minimum clinically important difference (MCID) was 1.0. The final BASDAI score was calculated using the following equation, in which 01 - 06 represents the question number: (BASDAI01 + BASDAI02 + BASDAI03 + BASDAI04 + BASDAI05/2 + BASDAI06*1.25/2)/5. The scale for question 6 was reduced to 0-8 since BASDAI06 was multiplied by 1.25. Data are reported as the mean change total score from baseline (Month 0).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The BASFI was a ten question, participant-reported measure that evaluated physical function. Each question was scored on a numerical rating scale that ranged from 0 (no functional impairment) to 10 (maximal impairment), and the MCID was 0.7. The mean of the ten questions was the total BASFI score. Data are reported as the mean change of total score from baseline (Month 0).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Number of Participants With Drug-Related Adverse Events (AEs)
Tidsramme: From signing of informed consent up to 24 months
An adverse event/adverse experience was any reaction, side effect or other untoward event associated with the use of a drug in humans, whether or not the event was considered drug related. This included adverse events occurring from accidental or deliberate drug overdose, from drug abuse, or from drug withdrawal. Exacerbations of pre-existing conditions are also considered adverse events. Data presented are adverse events that are drug-related and are detailed in the adverse event section of this report.
From signing of informed consent up to 24 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Number of Involved Peripheral Joints
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Peripheral joints were assessed by Tender Joint Counts (TJC) and Swollen Joint Counts (SJC), using pressure and joint manipulation during physical examination. Seventy-eight TJC and 76 SJC were evaluated and a score of 0 (not tender or swollen) or 1 (tender or swollen) was assigned for each joint with a higher total score indicating a greater number of involved joints.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Extraspinal Manifestations
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Extraspinal manifestations (enthesitis, dactylitis, uveitis, psoriasis, and Inflammatory Bowel Disease (IBD)) were assessed by investigators and reported on the basis of their clinical evaluation and participant records.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Erythrocyte Sedimentation Rate (ESR)
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Plasma concentrations of ESR were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Plasma Concentrations of C-Reactive Protein (CRP)
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Plasma concentrations of CRP were assessed as a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Bath Ankylosing Spondylitis-Global (BAS-G) Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The BAS-G was a participant-reported instrument with two items. In the first item, the participant rated the effect of their disease over the last week, and in the second item, the participant rated the effect of their disease over the previous 6 months. Each item of the BAS-G was scored on a scale ranging from 0 (no effect) to 10 (very severe effect). The mean of the two scores was the total BAS-G score and the MCID was 1.5.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Global Assessment of Disease Activity Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Global Assessment of Disease Activity was a participant-reported measure that evaluated disease activity. It was scored on a scale that ranged from 0 to 10; lower scores indicated better patient status.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Participant Fatigue Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Using the BASDAI questionnaire, participants assessed the overall level of fatigue/tiredness experienced by him/her. It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Participant Pain Score
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Using the BASDAI questionnaire, participants assessed the overall level of AS neck, back or hip pain experienced by him/her. It was scored on a numerical rating scale from 0 (no symptoms) to 10 (severe symptoms).
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Morning Stiffness
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Morning stiffness was a participant-reported assessment. The number of participants with morning stiffness were assessed at each visit.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Duration of Morning Stiffness
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Participants accessed the duration of morning stiffness in 15 minute intervals from 0 to 2 hours. Data are reported as the mean duration of morning stiffness ± standard deviation.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) Improvement Criteria
Tidsramme: At 3, 6, 9, 12, 18, and 24 months
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst). To qualify for a 20% improvement, participants were required to have an improvement of greater than or equal to 20% and greater than or equal to 1 unit in at least 3 domains, and no worsening of greater than or equal to 20% and greater than or equal to 1 unit in the remaining domain. To achieve a 40% improvement, participants were required to have an improvement of greater than or equal to 40% and greater than or equal to 2 units in at least 3 domains, and no worsening at all in the remaining domain.
At 3, 6, 9, 12, 18, and 24 months
Percentage of Participants Achieving ASAS Partial Remission Criteria
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
This is a four domain (participant global assessment of disease activity, assessment of spinal pain, assessment of function (BASFI), and assessment of duration/severity of morning stiffness (mean of BASDAI questions 5 and 6)), participant-reported assessment scored on a scale from 0 (best) to 10 (worst). To qualify for a partial remission, participants had to have values of 2 or less (on a scale of 10) in each of the 4 domains.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Impairment in Daily Activities During the Last 4 Weeks
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The impairment of daily activities was based on participant recall of events that occurred over the 4 weeks before the visit. Percentage of participants with impairment for 0, less than 7, 7 to 14, and greater than 14 days was assessed.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants Who Missed Work Days Due to Ankylosing Spondylitis (AS) in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Missed Work Days Due to Ankylosing Spondylitis in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Days of In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants on Adalimumab Monotherapy
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Concomitant Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Percentage of Participants With Concomitant Pain Relief/Anti-Inflammatory Agents
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Participants with concomitant pain relief/anti-inflammatory agents like analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, and systemic glucocorticoids were assessed during the study period.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
Mean Equivalent Dose of Prednisolone
Tidsramme: At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months
The mean equivalent dose of prednisolone was calculated based on the International Standard for comparison of different glucocorticoid products.
At Baseline (Month 0), 3, 6, 9, 12, 18, and 24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

AbbVie (prior sponsor, Abbott)

Efterforskere

  • Studieleder: Bianca Wittig, MD, AbbVie Deutschland GmbH & Co. KG, Medical Department

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. januar 2006

Primær færdiggørelse (Faktiske)

1. maj 2014

Studieafslutning (Faktiske)

1. maj 2014

Datoer for studieregistrering

Først indsendt

1. marts 2010

Først indsendt, der opfyldte QC-kriterier

2. marts 2010

Først opslået (Skøn)

3. marts 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

9. juli 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. juni 2015

Sidst verificeret

1. juni 2015

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • P10-147

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Ankyloserende spondylitis

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Russia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner